Release Date: December 5, 2025
Expiration Date: December 5, 2026
Activity Overview
The BURST CME™ format is an online, on-demand video program designed to deliver concise, modular education. In these modules, Hanford Yau, MD, and Stephen J. Greene, MD, review the relationship between hypercortisolism and hypertension, identifying patients with resistant hypertension who should be screened for hypercortisolism, and therapies for the management of hypercortisolism with concomitant hypertension.
Target Audience
This educational activity is directed toward cardiologists, endocrinologists, diabetologists, primary care physicians, nurses, NPs, PAs, and other health care professionals involved in the management of hypercortisolism in patients with hypertension.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify the role of hypercortisolism in the development of resistant hypertension
- Review risk factors for hypercortisolism in patients with resistant hypertension
- Implement screening recommendations to identify hypercortisolism in patients with resistant hypertension
- Evaluate clinical trial data for therapies for hypercortisolism
Hanford Yau, MD
Codirector of Duke Heart Failure
Medication Titration Clinic
Associate Professor, Division of
Cardiology
Duke Clinical Research Institute
Duke University School of Medicine
Durham,
North Carolina
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Corcept Therapeutics, Inc.
Stephen J. Greene, MD
Codirector
of Duke Heart Failure Medication Titration Clinic
Associate
Professor,
Division of Cardiology
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Corcept Therapeutics, CSL Vifor, Cytokinetics, Eli Lilly and Company, Idorsia, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Otsuka, PharamIN, Recordati, Roche Diagnostics, Sanofi, Sumitomo, Tricog Health; Grant/Research Funding: Otsuka, Novartis, Boehringer Ingelheim, AstraZeneca
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here